Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 9/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736581 | 1.00 | BCHE (0.57) | BCHEACHELMNARENTSHR | |
| Hydrochloric Acid SCHEMBL1572929 | 0.98 | BCHE (0.56) | BCHEACHELMNARENTSHR | |
| SCHEMBL8172047 | 0.83 | BCHE (0.53) | BCHEACHERENTSHRSLC6A2 | |
| SCHEMBL2977281 | 0.83 | BCHE (0.44) | BCHEACHERENSLC6A2SLC6A4 | |
| SCHEMBL7405178 | 0.83 | BCHE (0.44) | BCHEACHERENSLC6A2SLC6A4 | |
| SCHEMBL3181771 | 0.79 | GBA1 (0.55) | BCHEACHELMNARENTSHR | |
| SCHEMBL30456151 | 0.79 | BCHE (0.49) | BCHEACHERENSLC6A2SLC6A4 | |
| SCHEMBL30287794 | 0.78 | BCHE (0.60) | BCHEACHERENTSHRSLC6A2 | |
| SCHEMBL11380106 | 0.78 | BCHE (0.60) | BCHEACHERENTSHRSLC6A2 | |
| SCHEMBL14498487 | 0.78 | CCR5 (0.47) | BCHEACHELMNARENTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | PNP, MTAP, TYMP | BCHE 698/4885ACHE 1253/4885LMNA 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.